Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Glycosylation Gives Growth Advantage to Hypoxic Tumor Cells

By LabMedica International staff writers
Posted on 02 Sep 2012
Tumors survive in a microenvironment characterized by low oxygen levels (hypoxia) by shifting the metabolism of their cells away from the glycolytic pathway used by normal cells and onto the alternative pentose phosphate pathway.

The pentose phosphate pathway (also called the phosphogluconate pathway and the hexose monophosphate shunt) is a process that generates NADPH and pentoses (five-carbon sugars). More...
There are two distinct phases in the pathway. The first is the oxidative phase, in which NADPH is generated, and the second is the nonoxidative synthesis of five-carbon sugars. This pathway is an alternative to glycolysis. While it does involve oxidation of glucose, its primary role is anabolic rather than catabolic. For most organisms, it takes place in the cytosol.

Investigators at the California Institute of Technology (Pasadena, USA; www.caltech.edu) studied the role of the regulatory enzyme phosphofructokinase 1 (PFK1) in the transition of cancer cells from the glycolytic pathway to the pentose phosphate pathway.

PFK1 is the most important control site in the mammalian glycolytic pathway. This step is subject to extensive regulation since it is the committed step - the first irreversible reaction unique to the glycolytic pathway. This leads to a precise control of glucose, galactose, and fructose going down the glycolytic pathway. Before this enzyme's reaction, glucose-6-phosphate can potentially travel down the pentose phosphate pathway, or be converted to glucose-1-phosphate for glycogenesis.

The investigators reported in the August 24, 2012, issue of the journal Science that the action of PFK1 was modified under hypoxic conditions by O-GlcNAcylation of the protein's amino acid serine located at position 529. This posttranslational addition of a sugar residue was orchestrated by O-linked beta-N-acetylglucosamine (O-GlcNAc).

Glycosylation inhibited PFK1 activity and redirected glucose flux through the pentose phosphate pathway, thereby conferring a selective growth advantage on cancer cells. Blocking glycosylation of PFK1 at serine 529 reduced cancer cell proliferation in vitro and impaired tumor formation in vivo.

"We have identified a novel molecular mechanism that cancer cells have coopted in order to produce intermediates that allow them to grow more rapidly and to help them combat oxidative stress," said senior author Dr. Linda Hsieh-Wilson, professor of chemistry at the California Institute of Technology. "What is unique here is that the addition of GlcNAc is dynamic and reversible. This allows a cancer cell to more rapidly alter its metabolism depending on the environment that it encounters."

Related Links:
California Institute of Technology


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.